Although the immunotherapy combination regimen has shown good data and safety during the perioperative period of gastric cancer, more clinical studies are still needed to explore the treatment regimens, the number of treatment cycles, the screening of beneficiary populations, and the safety assessment of different drug combinations of immunotherapy combination therapy as adjuvant treatment after gastric cancer surgery.

开始日期2025-07-01

申办/合作机构

天津市肿瘤医院（天津医科大学肿瘤医院）

NCT07031154

/ Not yet recruiting临床2期IIT

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.

开始日期2025-06-30

申办/合作机构

厦门大学附属第一医院（厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所）

NCT07041437

/ Not yet recruiting临床2期IIT

Efficacy and Safety Study of SHR-A2102-based Treatment in Advanced Breast Cancer

Our study is aimed to evaluate the efficacy and safety of SHR-A2102 combined other antitumor treatments in advanced breast cancer.

开始日期2025-06-30

申办/合作机构

复旦大学

100 项与阿得贝利单抗相关的临床结果

登录后查看更多信息

100 项与阿得贝利单抗相关的转化医学

登录后查看更多信息

100 项与阿得贝利单抗相关的专利（医药）

登录后查看更多信息

项与阿得贝利单抗相关的文献（医药）

2025-06-01·BMJ Open

Clinical study of adebrelimab in combination with apatinib and irinotecan for PD-1 inhibitor-ineffective advanced-stage gastric cancer: study protocol for a single-arm, single-centre, exploratory trial

Article

作者: Xia, Xiang ; Guan, Yujing ; Bai, Long ; Aimaiti, Muerzhate ; Zhang, Hao-yu ; Wang, Shuchang ; Ni, Bo ; Yue, Ben ; Gu, Jiayi ; Liu, Tao ; Zhang, Zizhen ; Zhang, Yeqian

Introduction:

Immunotherapy has revolutionised cancer treatment. Immune checkpoint inhibitors have demonstrated significant efficacy across multiple tumour types, including gastric cancer, where several approved programmed cell death 1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitors show promising antitumour activity. While PD-L1 expression serves as a predictive biomarker for PD-1 inhibitor response, and PD-L1-positive patients generally show better outcomes, therapeutic resistance remains a challenge. Many initial responders eventually develop resistance, and surprisingly, some PD-L1-positive patients fail to achieve expected response rates, indicating emerging resistance mechanisms in potentially responsive populations. Adebrelimab, a PD-L1 inhibitor, demonstrates mechanistic advantages over PD-1 inhibitors, with clinical studies suggesting promising therapeutic potential. When combined with irinotecan, apatinib has shown efficacy in second-line gastric cancer treatment. This study aims to evaluate the efficacy and safety of combining adebrelimab with apatinib and irinotecan for advanced gastric cancer refractory to PD-1 inhibitors.

Method and analysis:

This single-arm, single-centre exploratory trial will be conducted at Renji Hospital, enrolling 32 patients aged 18–75 years. Eligible patients must have initially achieved partial response, complete response or stable disease with progression-free survival (PFS)≥3 months during prior immunotherapy but subsequently progressive disease on imaging. Treatment will continue until meeting discontinuation criteria. The primary endpoint is objective response rate with Clopper-Pearson 95% CI. Secondary endpoints include disease control rate (95% CI), PFS and overall survival (estimated by Kaplan-Meier method), along with safety assessments.

Ethics and dissemination:

All participants will provide informed consent. The protocol has been approved by the Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee (LY2023-201-C). The results will be disseminated through peer-reviewed manuscripts, reports and presentations.

Trial registration number:

ChiCTR2300077329.

2025-05-01·Clinical Lung Cancer

Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Article

作者: Zhang, Jiexia ; Zhou, Chengzhi ; Xie, Zhanhong ; Liu, Ming ; Lin, Xinqing ; Qin, Yinyin ; Guan, Wenhui ; Xu, Xin ; Li, Zekun ; Xie, Xiaohong ; Huang, Zhenqian ; Qiu, Guihuan

BACKGROUND:

Small cell lung cancer (SCLC) is initially highly sensitive to chemotherapy, which often leads to significant tumor reduction. However, the majority of patients eventually develop resistance, and the disease is further complicated by its "cold" tumor microenvironment, characterized by low tumor immunogenicity and limited CD8+ T cell infiltration. These factors contribute to the poor response to immunotherapy in many cases of extensive-stage SCLC (ES-SCLC). High-dose chemotherapy has shown potential in enhancing tumor cytoreduction, but its use is often limited by severe hematologic toxicity. Combining chemotherapy with immune checkpoint inhibitors (ICIs) can create a synergistic effect by promoting immunogenic cell death and enhancing immune activation. Autologous hematopoietic stem cell transplantation (auto-HSCT) provides a means to support hematopoietic recovery, mitigate chemotherapy-induced myelosuppression, and contribute to immune reconstitution. In this context, the integration of auto-HSCT with dose-intensified chemotherapy and ICIs aims to both protect the bone marrow and enhance antitumor immune responses, potentially overcoming resistance to immunotherapy in ES-SCLC.

METHODS:

A phase I, single-center, single-arm trial was designed to evaluate the safety and efficacy of auto-HSCT-supported dose-intensified chemotherapy combined with adebrelimab in treatment-naive ES-SCLC patients. Participants will receive induction chemotherapy followed by stem cell mobilization, apheresis, and cryopreservation. After successful mobilization, consolidation chemotherapy with stem cell reinfusion and granulocyte colony-stimulating factor (G-CSF) support will be performed. Maintenance therapy with adebrelimab continues until disease progression or unacceptable toxicity. Safety and efficacy data, including adverse events, objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), will be analyzed.

RESULTS:

The study aims to enhance treatment outcomes by overcoming resistance to immuno-chemotherapy and promoting immune reconstitution. The trial is ongoing at the First Affiliated Hospital of Guangzhou Medical University.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT06597513.

2025-04-01·Cancer Communications

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2‐ breast cancer‐FINEST study

Article

作者: Liu, Guang‐Yu ; Li, Jun‐Jie ; Wu, Wen‐Ya ; Liang, Fei ; Wu, Jiong ; Yu, Ke‐Da ; Chen, Li ; Di, Gen‐Hong ; Wang, Zhong‐Hua ; Fan, Lei ; Shao, Zhi‐Ming

Abstract:

Background:

Hormone receptor‐positive (HR+)/humaal growth factor receptor 2‐negative (HER2‐) breast cancer, the most common breast cancer type, has variable prognosis and high recurrence risk. Neoadjuvant therapy is recommended for median‐high risk HR+/HER2‐ patients. This phase II, single‐arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2‐ breast cancer patients.

Methods:

Eligible female patients with newly diagnosed, untreated HR+/HER2‐ breast cancer received 2 cycles of nab‐paclitaxel and carboplatin (nabPCb). Magnetic resonance imaging (MRI) was performed to assess tumor responses, and 40% regression of the maximal tumor diameter was deemed chemo‐sensitive. Chemo‐sensitive patients continued nabPCb for 4 more cycles (group A). Chemo‐insensitive patients were randomized to groups B, C, and D at a ratio of 1:3:1 to receive a new chemotherapy for 4 cycles or endocrine‐immune‐based therapy (dalpiciclib, letrozole and adebrelimab, with goserelin if patients were premenopausal) for 4 cycles or to undergo surgery. Peripheral blood and core‐needle biopsy (CNB) samples were collected before treatment, followed by a next‐generation sequencing (NGS) panel detection and similarity network fusion (SNF) typing through digital pathology data. The primary endpoint was the pathological complete response (pCR) rate, and the secondary endpoint was the clinical objective response rate (ORR).

Results:

A total of 121 patients were enrolled (67.8% with stage III disease), with 76, 9, 27, and 9 patients in groups A, B, C and D, respectively. The total pCR rate was 4.1%, and all patients who received pCR were in group A. Group C had a better ORR than Group B (81.5% vs. 66.7%). Exploratory analysis revealed that patients with the SNF4 subtype were the most sensitive to nabPCb (pCR rate of 21.1% vs. 1.8% in group A), whereas patients in group C with the SNF2 subtype were more sensitive to endocrine‐immune‐based therapy (Miller‐Payne grade 4‐5, 45.5% vs. 6.3%).

Conclusions:

Converting to endocrine‐immune‐based therapy improved the ORR, but not the pCR rate in chemo‐insensitive patients. Neoadjuvant chemotherapy and endocrine therapy are not mutually exclusive. The SNF4 subtype of HR+/HER2‐ breast cancer was more chemo‐sensitive, whereas the SNF2 subtype might be more sensitive to immunotherapy.

327

项与阿得贝利单抗相关的新闻（医药）

2025-07-01

·ioncology

ESMO GI 2025明日启幕，中国消化道肿瘤前沿声音响彻巴塞罗那

编者按：2025年7月2日-5日，欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于西班牙巴塞罗那盛大召开，汇聚全球消化道领域最新诊疗观念与进展，包括704篇讲题和427篇壁报。此次会上，中国学者贡献了39项讲题，其中包括2项最新突破性摘要（LBA）、2项微型口头报告（MO）、1项教育主题汇报（Education Session）和34篇壁报（Poster）。现将中国之声整理如下，以飨读者。最新突破性摘要（LBA）摘要号：LBA1研究名称：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND TrialFIND试验中期分析：ctDNA甲基化动态监测指导非转移性结直肠癌术后随访讲者：彭俊杰 | 复旦大学附属肿瘤医院会场：Room Madrid时间：7月4日 16:30 - 16:40（当地时间）摘要号：LBA2研究名称：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)TALENTACE研究：比较按需TACE联合阿替利珠单抗+贝伐珠单抗(Atezo+Bev)与单纯按需TACE治疗未经系统治疗的中高肿瘤负荷不可切除肝细胞癌（uHCC）的III期开放标签随机对照研究讲者：韩国宏 | 西安国际医学中心医院会场：Room Barcelona时间：7月3日 14:50 - 15:00（当地时间）微型口头报告（Mini Oral）摘要号：149MO研究名称：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 StudyABSK-011-201研究II期最新结果：依帕戈替尼（ABSK-011）联合阿替利珠单抗用于FGF19过表达型晚期肝细胞癌（HCC）的一线治疗及用于经免疫检查点抑制剂（ICIs）治疗患者的疗效分析讲者：程琪 | 华中科技大学同济医学院附属同济医院会场：Room Barcelona时间：7月2日 17:15 - 17:20（当地时间）摘要号：150MO研究名称：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosisSIERRA研究IIIb期安全性分析：度伐利尤单抗（D）联合替西木单抗（T）一线治疗伴临床预后不良特征的肝细胞癌（HCC）患者讲者：Stephen L. Chan | 香港中文大学会场：Room Barcelona时间：7月2日 17:20 - 17:25（当地时间）教育专题会（Education Session）讲题：New medical treatment in 2025 beyond IO combinations2025年突破免疫联合疗法的新兴医学治疗方向讲者：Stephen L. Chan | 香港中文大学会场：Room Madrid时间：7月3日 12:00 - 12:20（当地时间）壁报（Poster）01结直肠癌摘要号：11P研究名称：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I StudyNALIRIFOX联合靶向治疗一线治疗转移性结直肠癌的I期研究讲者：Haojie Zhou | 复旦大学附属中山医院摘要号：49P研究名称：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer转移性结直肠癌一线诱导治疗后维持策略与治疗间歇的多中心倾向性评分匹配比较研究讲者：Ka Yan Lai | 伊利沙伯医院摘要号：65P研究名称：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal CancerBETTER研究：替雷利珠单抗+贝伐珠单抗+TAS102+SBRT三线治疗MSS/pMMR转移性结直肠癌的开放标签单臂试验讲者：张群 | 南京鼓楼医院摘要号：98P研究名称：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth一种预测早期结直肠癌浸润深度的整合分子标志物的新型风险分层模型讲者：Bing Li | 复旦大学附属中山医院摘要号：130eP研究名称：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer从循证到实践：MSS/MSI-L结直肠癌免疫治疗的多中心真实世界研究与Meta分析讲者：Yue T. Gou | 中南大学湘雅医院摘要号：131eP研究名称：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment贝伐珠单抗+奥沙利铂+伊立替康三联方案治疗氟尿嘧啶经治转移性结直肠癌的疗效与安全性讲者：韩璐 | 中国人民解放军总医院第五医学中心摘要号：139eP研究名称：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)中国结直肠癌MSI/MMR检测与治疗实践全国调研（SUMMER研究）讲者：王正航 | 北京大学肿瘤医院摘要号：146TiP研究名称：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progressMIRACLE3研究：依沃西单抗联合放化疗一线治疗MSS型不可切除肝/肺转移结直肠癌的II期试验（进行中）讲者：李心翔 | 复旦大学附属肿瘤医院摘要号：224P研究名称：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)SPRING-01研究：短程放疗序贯信迪利单抗+CAPOX全直肠新辅助治疗局部进展期直肠癌的前瞻性随机对照试验讲者：田锋 | 山东第一医科大学附属省立医院摘要号：226P研究名称：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results阿得贝利单抗+短程放疗+CAPOX全新辅助治疗pMMR局部进展期直肠癌的中期分析讲者：靖昌庆 | 山东第一医科大学附属省立医院摘要号：229P研究名称：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)高风险局部进展期直肠癌新辅助放化疗±FOLFOXIRI强化治疗的随机研究：临床与生存质量分析（NCT03997435）讲者：Ka Yan Lai | 伊利沙伯医院02肝胆胰肿瘤摘要号：157P研究名称：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analysesCheckMate 9DW研究拓展分析：纳武利尤单抗联合伊匹木单抗 vs 仑伐替尼或索拉非尼一线治疗中国不可切除/晚期肝细胞癌患者讲者：秦叔逵 | 中国药科大学附属南京天印山医院摘要号：183P研究名称：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population中性粒细胞-淋巴细胞比值（NLR）与PLR、LMR、SII、PNI在肝癌冷冻消融术患者中的预后价值比较及最佳适用人群探索讲者：李家平 | 中山大学附属第一医院摘要号：195P研究名称：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinomaCOVID-19、肝硬化与肝细胞癌关联机制的生物信息学与系统生物学研究讲者：Xianxiang Chen | 广西医科大学第一附属医院摘要号：203eP研究名称：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis基于cfDNA生物标志物与人工智能模型的肝癌早期筛查：系统评价与Meta分析讲者：Minh Le | 台北医学大学摘要号：206eP研究名称：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib基线ALBI分级对接受仑伐替尼治疗的肝细胞癌患者预后的影响讲者：商昌珍 | 中山大学孙逸仙纪念医院摘要号：209eP研究名称：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT MechanismRPL41通过转录因子RUNX2介导的上皮间质转化（EMT）机制促进肝细胞癌转移讲者：Zheng A. Hua | 重庆大学附属沙坪坝医院摘要号：302P研究名称：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer索凡替尼联合吉西他滨及白蛋白结合型紫杉醇用于可切除/临界可切除胰腺癌新辅助治疗讲者：高松 | 天津市肿瘤医院摘要号：313P研究名称：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancerABHD17C介导的BCL6B蛋白S-去棕榈酰化通过激活CD24转录抵抗胰腺癌巨噬细胞吞噬讲者：Yalu Zhang | 中国科学技术大学附属第一医院摘要号：317P研究名称：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity肿瘤微环境芯片：异质性下免疫治疗疗效的实时观测窗口讲者：Chiao-Min Lin | 台湾清华大学摘要号：358P研究名称：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study胆道癌根治术后辅助化疗方案的疗效比较：单中心回顾性队列研究讲者：Wen-Ying Lin | 台北荣民总医院03胃食管癌摘要号：394P研究名称：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials卡瑞利珠单抗为基础治疗食管鳞癌的反应性皮肤毛细血管内皮增生（RCCEP）：两项III期试验的合并分析讲者：骆卉妍 | 中山大学肿瘤防治中心摘要号：396P研究名称：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy卡博替尼联合阿替利珠单抗用于含铂化疗失败的复发/转移性食管鳞癌（R/M ESCC）患者：单臂II期研究讲者：Hung-Yang Kuo | 台湾大学医学院附设医院摘要号：399P研究名称：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic ReprogrammingARL5B通过ROCK1-SREBP1介导代谢重编程驱动食管鳞癌进展的机制研究讲者：Xinyue Ma | 山东大学齐鲁医院摘要号：418P研究名称：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study纳武利尤单抗一线治疗晚期胃/胃食管结合部腺癌的真实世界研究结局：多中心回顾性观察研究讲者：邱红 | 华中科技大学同济医学院附属同济医院摘要号：419P研究名称：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)SURPASS研究：中国晚期胃/胃食管结合部癌（GC/GEJC）真实世界治疗模式与生物标志物检测现状调研讲者：Rongrui Liu | 中国人民解放军总医院摘要号：424P研究名称：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study化疗（SOX）联合替雷利珠单抗治疗胃癌肝转移：一项多中心II期研究的首次报告讲者：康牧星 | 浙江大学医学院附属第二医院摘要号：430P研究名称：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical TrialCLDN18.2特异性CAR-T细胞（CT041）治疗胃癌的应答与耐药特征解析：I期临床试验探索性生物标志物分析讲者：彭浩欣 | 北京大学肿瘤医院摘要号：436P研究名称：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions肝切除改善原发性病灶切除的胃癌肝转移患者预后讲者：Yun Feng | 复旦大学附属肿瘤医院04其他摘要号：219eP研究名称：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study转移性胃肠间质瘤行肿瘤细胞减灭术的预后因素分析：一项回顾性队列研究讲者：Haidong Zhang | 四川大学华西医院摘要号：495P研究名称：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction初始剂量减量策略改善老年胃肠道肿瘤患者化疗耐受性的优化研究讲者：Wendy W. Chan | 香港玛丽医院摘要号：499P研究名称：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapyTACR1基因型与含奥氮平止吐方案防治化疗相关性呕吐的疗效关联研究讲者：Winnie Yeo | 香港中文大学摘要号：505eP研究名称：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers安罗替尼治疗贝伐珠单抗经治胃肠道肿瘤的真实世界疗效讲者：陈锦章 | 南方医科大学南方医院摘要号：506eP研究名称：Impact of CARG-Guided Dose Adjustment of Anticancer Therapy on Adverse Events in Chinese Elderly Cancer Patients: A Prospective Study基于CARG评估指导抗肿瘤治疗剂量调整对中国老年癌症患者不良事件的影响：前瞻性研究讲者：葛郁平 | 北京协和医院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期免疫疗法临床结果

2025-07-01

·肿瘤界

2025 ESMO GI | 中国智慧闪耀国际：入选研究一览

点击蓝字关注我们前言一年一度的欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于2025年7月2日~5日在巴塞罗那召开。日前，大会官网披露了摘要标题，其中34项中国研究入选。整理如下，和您一起先睹为快！胃食管癌1摘要号：394P研究名称（英文）：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials 讲者：骆卉妍 | 中山大学肿瘤防治中心2摘要号：396P研究名称（英文）：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy 讲者：Hung-Yang Kuo | 台湾大学医学院附设医院3摘要号：399P研究名称（英文）：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic Reprogramming 讲者：Xinyue Ma | 山东大学齐鲁医院4摘要号：418P研究名称（英文）：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study 讲者：邱红 | 华中科技大学同济医学院附属同济医院5摘要号：419P研究名称（英文）：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)讲者：Rongrui Liu | 中国人民解放军总医院6摘要号：424P研究名称（英文）：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study 讲者：康牧星 | 浙江大学医学院附属第二医院7摘要号：430P研究名称（英文）：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial 讲者：彭昊昕 | 北京大学肿瘤医院8摘要号：436P研究名称（英文）：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions讲者：Yun Feng | 复旦大学附属肿瘤医院肝胆胰肿瘤1摘要号：LBA2研究名称（英文）：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) 讲者：韩国宏 | 西安国际医学中心医院2摘要号：149MO研究名称（英文）：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study讲者：程琪 | 华中科技大学同济医学院附属同济医院3摘要号：150MO研究名称（英文）：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis讲者：Stephen L. Chan | 香港中文大学4摘要号：157P研究名称（英文）：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses 讲者：秦叔逵 | 中国药科大学附属南京天印山医院5摘要号：183P研究名称（英文）：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population讲者：李家平 | 中山大学附属第一医院6摘要号：195P研究名称（英文）：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma讲者：Xianxiang Chen | 广西医科大学第一附属医院7摘要号：203eP研究名称（英文）：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis讲者：Minh Le | 台北医学大学8摘要号：206eP研究名称（英文）：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib讲者：商昌珍 | 中山大学孙逸仙纪念医院9摘要号：209eP研究名称（英文）：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism讲者：Zheng Hua | 重庆大学附属沙坪坝医院10摘要号：302P研究名称（英文）：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer讲者：高松 | 天津市肿瘤医院11摘要号：313P研究名称（英文）：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer讲者：Yalu Zhang | 中国科学技术大学附属第一医院12摘要号：317P研究名称（英文）：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity讲者：Chiao-Min Lin | 台湾清华大学13摘要号：358P研究名称（英文）：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study讲者：Wen-Ying Lin | 台北荣民总医院结直肠癌1摘要号：LBA1研究名称（英文）：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND Trial讲者：彭俊杰 | 复旦大学附属肿瘤医院2摘要号：11P研究名称（英文）：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study讲者：Haojie Zhou | 复旦大学附属中山医院3摘要号：49P研究名称（英文）：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer讲者：Connie Ka Yan Lai | 伊利沙伯医院4摘要号：65P研究名称（英文）：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer 讲者：张群 | 南京鼓楼医院5摘要号：98P研究名称（英文）：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth讲者：Bing Li | 复旦大学6摘要号：130eP研究名称（英文）：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer讲者：Yue Gou | 中南大学7摘要号：131eP研究名称（英文）：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment讲者：韩璐 | 中国人民解放军总医院第五医学中心8摘要号：139eP研究名称（英文）：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)讲者：王正航 | 北京大学肿瘤医院9摘要号：146TiP研究名称（英文）：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress讲者：李心翔 | 复旦大学附属肿瘤医院10摘要号：224P研究名称（英文）：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)讲者：Feng Tian | 山东第一医科大学附属省立医院11摘要号：226P研究名称（英文）：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results讲者：靖昌庆 | 山东第一医科大学附属省立医院12摘要号：229P研究名称（英文）：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)讲者：Ka Yan Lai | 伊利沙伯医院胃肠道罕见肿瘤1摘要号：219eP研究名称（英文）：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study 讲者：Haidong Zhang | 四川大学华西医院其他1摘要号：495P研究名称（英文）：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction讲者：Wendy W. Chan | 香港大学李嘉诚医学院2摘要号：499P研究名称（英文）：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy讲者：Winnie Yeo | 香港中文大学3摘要号：505eP研究名称（英文）：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers讲者：陈锦章 | 南方医科大学南方医院备注：如有遗漏或任何问题，请给我们留言~声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通消化系统肿瘤编辑：lagertha审核：南星

临床结果细胞疗法临床2期免疫疗法

2025-06-26

·汇聚南药

“医药一哥”大爆发！

在医药行业的激烈竞争中，“医药一哥”恒瑞医药始终以创新为驱动，陆续迎来了重大突破。近日，其自主研发的六款创新药物及联合疗法获得国家药品监督管理局(NMPA)颁发的《药物临床试验批准通知书》，即将开展针对实体瘤的临床试验，这无疑为其在肿瘤领域的布局添上了浓墨重彩的一笔。这六款获批的创新药各具特色。SHR2554片作为新型口服EZH2抑制剂，致力于恶性肿瘤治疗。全球同类药物Tazverik在2024年销售额约5100万美元。注射用SHR-A1811是靶向HER2的抗体偶联药物(ADC)，已于2025年5月获批上市，用于HER2阳性非小细胞肺癌。同类产品Kadcyla、Enhertu等在2024年全球销售额合计超65亿美元。注射用SHR-A2102靶向Nectin-4，全球仅一款同类产品Padcev上市，2024年销售额19.49亿美元。阿得贝利单抗注射液作为抗PD-L1单抗，2023年已获批用于小细胞肺癌一线治疗，同类产品Atezolizumab等2024年全球销售额96.48亿美元。此外，注射用SHR-A1904靶向Claudin18.2，适应症覆盖胃癌、胰腺癌等，研发投入1.43亿元，针对高发癌种进行精准打击。SHR-1701注射液作为抗PD-L1/TGF-βRII双功能融合蛋白，全球尚无同类产品上市。从试验方案来看，SHR2554将联合或不联合阿得贝利单抗、SHR-1701等药物，或与醋酸阿比特龙等联用，积极探索实体瘤治疗潜力。这一系列联合用药方案充分利用了不同药物的作用机制，有望产生协同效应，提高治疗效果。不过，恒瑞医药也明确表示，将按法规推进临床试验，同时需注意研发周期长、审批不确定性等风险。创新药研发之路本就布满荆棘，从实验室到临床再到最终上市，每一步都充满挑战。恒瑞医药在肿瘤领域的布局由来已久且成果丰硕。在研发投入上，该公司近十年来累计创新投入超过300亿元，先后在连云港、上海、成都、美国和欧洲等地设立了研发中心，打造了一支5000多人的全球研发团队。从靶点研究、临床前研究、转化医学研究、临床试验到新药注册上市的药物开发全过程，建立了完善的研发管理体系。在产品布局方面，公司已上市的17款创新药中抗肿瘤创新药达9款，另有90多个自主创新产品正在临床开发，300多项临床试验在国内外开展。2024年年报显示，肿瘤产品收入增长19.39%至145.87亿元，创新药销售收入达138.92亿元(含税，不含对外许可收入)，同比增长30.60%。此次多款创新药同步获批临床，进一步丰富了恒瑞在肿瘤领域的管线布局。一方面，为后续的产品梯队建设提供了有力支撑，在当前竞争激烈的肿瘤药市场中，丰富的管线意味着更多的发展机遇和更强的抗风险能力。另一方面，有望提升其全球竞争力。在国际舞台上，恒瑞医药已连续多年携重磅研究成果参加如美国临床肿瘤学会(ASCO)年会等国际盛会，通过展示创新成果，提升了品牌影响力。喜欢我们文章的朋友点个“在看”和“赞”吧，不然微信推送规则改变，有可能每天都会错过我们哦~免责声明“汇聚南药”公众号所转载文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请在留言栏及时告知，我们会在24小时内删除相关信息。信息来源：制药网往期推荐本平台不对转载文章的观点负责，文章所包含内容的准确性、可靠性或完整性提供任何明示暗示的保证。

抗体药物偶联物申请上市信使RNA上市批准

100 项与阿得贝利单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16412

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
广泛期小细胞肺癌	中国	上海盛迪医药有限公司	2023-02-28

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌层浸润性膀胱癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2025-04-25
晚期肝细胞癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2024-10-28
非鳞状非小细胞肺癌	临床3期	中国	上海盛迪医药有限公司	2024-03-29
非鳞状非小细胞肺癌	临床3期	中国	苏州盛迪亚生物医药有限公司	2024-03-29
局限期小细胞肺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2021-01-20
非小细胞肺癌IIIB期	临床3期	中国	江苏恒瑞医药股份有限公司	2020-07-14
可切除非小细胞肺癌	临床3期	中国	江苏恒瑞医药股份有限公司	2020-07-10
HER2阳性胆道肿瘤	临床2期	中国	苏州盛迪亚生物医药有限公司	2025-02-26
家族性肝硬化伴肺动脉高压	临床2期	中国	江苏恒瑞医药股份有限公司	2025-01-22
不可切除的肝内胆管癌	临床2期	中国	江苏恒瑞医药股份有限公司	2025-01-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04303988 (ASCO2025) 人工标引	临床2期	三阴性乳腺癌	35	Adebrelimab + Bevacizumab + Cisplatin/Carboplatin	簾鬱鑰蓋憲選築鹽齋遞(淵顧簾鑰膚構襯選觸觸) = 醖選窪顧壓憲獵廠壓襯淵襯鑰糧願壓襯鏇範鹽 (艱鬱願廠顧淵鹽構艱憲 ) 更多	积极	2025-05-30
ChiCTR2300078869 (ASCO2025)	临床2期	肝内胆管癌二线 HBV infection history	10	Adebrelimab + Lenvatinib	鬱鹽艱淵製憲艱構築築(積繭鹹獵糧憲鏇積憲網) = 鹽窪蓋餘鹹獵淵遞顧積鹹壓選築觸夢簾鬱網餘 (醖鑰鑰窪觸鑰繭製獵鹽 ) 更多	积极	2025-05-30
NCT06016413 (Phase II study of adebrelimab plus carboplatin and albumin-bound taxanol in head and neck squamous cell carcinoma, ASCO2025)	临床2期	局部晚期头颈部鳞状细胞癌新辅助 PD-L1	30	Adebrelimab + Carboplatin + Albumin-bound Paclitaxel	齋鏇衊製餘獵構構繭遞(顧窪鏇簾憲壓鑰鏇壓製) = 積鏇蓋鬱鏇糧糧鏇蓋淵範遞觸繭夢襯願鏇網築 (遞鏇鹹膚壓糧觸淵壓廠 ) 更多	积极	2025-05-30
NCT06299371 (ESMO_ELCC2025)	临床2期	EGFR突变的非小细胞肺癌新辅助 \| 辅助 EGFR mutations	-	Adebrelimab + Albumin-bound paclitaxel + Carboplatin/Cisplatin	獵選觸蓋蓋艱構壓願顧(繭願壓蓋遞築鹽觸鹽餘) = 膚蓋選淵網積襯觸鑰願繭顧願觸鏇積夢廠鏇齋 (網獵遞餘淵衊網夢觸齋 ) 更多	-	2025-03-26
CAPSTONE-1 (ESMO_ELCC2025)	N/A	广泛期小细胞肺癌	75	Adebrelimab-based therapy	夢醖遞夢壓衊衊艱廠夢(鑰簾繭衊範憲夢遞繭憲) = 艱積鬱夢鹹鑰憲醖網積願鏇觸齋顧製憲衊艱糧 (製齋夢構願衊鑰鏇鑰鹽, 54.8 ~ 77.1) 更多	积极	2025-03-26
ChiCTR2300069179 (ASCO_GI2025) 人工标引	临床2期	局部晚期食管鳞状细胞癌辅助 \| 新辅助	36	Adebrelimab + Paclitaxel + Cisplatin	齋獵網艱願範構艱製糧(齋淵積壓齋鏇糧鏇廠築) = 淵膚艱襯鹹繭簾膚鏇積鹹衊艱鏇鏇夢構淵願廠 (壓廠窪繭鏇顧鹽遞憲醖 ) 更多	积极	2025-01-23
NCT06178211 (ASCO_GI2025) 人工标引	临床2期	局部晚期食管鳞状细胞癌新辅助	36	Adebrelimab + Chemotherapy	艱鏇簾鑰廠廠襯鏇憲壓(糧顧獵衊衊鬱壓顧鏇構) = 鏇製鹽鹹鏇獵鬱觸膚選製積壓顧糧醖積鏇糧膚 (築夢鏇積齋製網鹽製顧, 23.1 ~ 56.5) 更多	积极	2025-01-23
NCT06178211 (ASCO_GI2025) 人工标引	临床2期	局部晚期食管鳞状细胞癌新辅助	36	Adebrelimab + Chemotherapy (Surgery)	艱鏇簾鑰廠廠襯鏇憲壓(糧顧獵衊衊鬱壓顧鏇構) = 選淵顧選鬱膚憲淵壓窪製積壓顧糧醖積鏇糧膚 (築夢鏇積齋製網鹽製顧, 24.6 ~ 59.3) 更多	积极	2025-01-23
ESMO_IO2024 人工标引	N/A	广泛期小细胞肺癌一线	188	Adebrelimab-based regimen	齋衊鬱繭憲繭積築積窪(鏇淵範壓顧觸網積鹹襯) = 餘廠製鑰選顧顧膚襯願齋夢衊鏇顧願艱齋膚鹽 (衊遞獵網憲簾淵繭襯製 ) 更多	积极	2024-12-12
ADBL-LC-001 (ESMO_IO2024) 人工标引	N/A	小细胞肺癌一线	143	Adebrelimab (ES-SCLC)	糧簾夢醖糧餘鬱顧艱構(範壓鬱壓糧遞齋鏇觸遞) = 構繭繭願膚構顧膚鹽衊觸醖遞範襯齋淵廠鏇顧 (遞衊膚鏇憲築簾獵糧夢, 10.0 ~ 14.9) 更多	积极	2024-12-12
ADBL-LC-001 (ESMO_IO2024) 人工标引	N/A	小细胞肺癌一线	143	Adebrelimab (LS-SCLC)	糧簾夢醖糧餘鬱顧艱構(範壓鬱壓糧遞齋鏇觸遞) = 選艱積襯選選構淵顧製觸醖遞範襯齋淵廠鏇顧 (遞衊膚鏇憲築簾獵糧夢, 13.7 ~ NA) 更多	积极	2024-12-12
NCT06198465 (ESMO_IO2024) 人工标引	临床2期	胃食管交界处腺癌新辅助	15	Adebrelimab + nab-paclitaxel + lobaplatin + S-1	襯糧醖網鹹廠艱築衊醖(繭襯繭鑰構蓋鹹鑰範範) = 構餘醖觸獵夢築淵鹹鏇願網淵淵簾顧獵繭範衊 (簾鹽願餘蓋簾鏇築蓋鬱 ) 更多	积极	2024-12-12